<DOC>
	<DOCNO>NCT02937558</DOCNO>
	<brief_summary>This Phase 2 , multi-center , randomize , placebo-controlled , double-blind trial open-label follow-up design assess efficacy Xeris Glucagon deliver continuous subcutaneous infusion prevent hypoglycemia lower intravenous glucose infusion rate child &lt; 1 year age congenital hyperinsulinism .</brief_summary>
	<brief_title>CSI-Glucagon Prevention Hypoglycemia Children With Congenital Hyperinsulinism</brief_title>
	<detailed_description>This Phase 2 , multi-center , randomize , placebo-controlled , double-blind parallel group study open-label follow-up design evaluate efficacy CSI-Glucagon™ prevention hypoglycemia lower IV glucose infusion rate deliver subcutaneously patient 1 year age congenital hyperinsulinism . CSI-Glucagon™ expect provide well inpatient treatment option compare current standard care . The study consist three phase : 1 . Baseline Phase : First baseline stabilization phase least 24 hour , concomitant therapy octreotide diazoxide safely wean continuous enteric feed hold constant degree possible , factor vary meal size IV glucose infusion rate ( GIR ) adjust set plasma glucose measurement drive algorithm . 2 . Blinded , Randomized Treatment Phase : Following stabilization phase , subject randomly assign blind treatment either glucagon placebo , deliver 48 hour OmniPod® infusion pump controller set start basal rate glucagon 5 μg/kg/hr GIR adjustment use maintain euglycemia . After 48 hour blind treatment , subject transition open-label active treatment . However , GIR reduction baseline &lt; 20 % 24 hour , subject transition early open-label phase . 3 . Open-label Treatment Phase : The third study period involve use CSI-Glucagon™ manage blood glucose minimal GIR 28 day cumulative exposure .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Diagnosed hyperinsulinism : a. Biochemical ; detectable insulin ( i.e. , ≥1 µIU/L ) time hypoglycemia , and/or suppress free fatty acid ( FFA ) , and/or suppress betahydroxybutyrate ( BOHB ) and/or glycemic response glucagon time hypoglycemia . 2 . Absolute necessity intravenous glucose prevent hypoglycemia : 1 . Having fail diazoxide therapy define inadequacy diazoxide eliminate need IV glucose , necessarily diazoxide effect . 2 . May diazoxide and/or octreotide , drug wean prior randomization . 3 . May dextrose feed . 3 . Patient may participant study protocol observational study , long investigational intervention take place within 24 hr . prior screening . 4 . Less 12 month age screening . 1 . History allergy glucagon excipients CSIGlucagon formulation . 2 . Currently receive , less 24 hour remove IV glucagon treatment , prior start study drug . 3 . Diazoxide naïve within five day start diazoxide . 4 . Receiving steroids dos large 20 mg/m2/day ( hydrocortisone equivalent ) . 5 . Patients sepsis . 6 . Receiving alpha beta agonist blood pressure support . 7 . Received investigational study drug within 5 halflives drug . 8 . Body weight less equal 2.3 kg/5.0 lb .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hypoglycemia</keyword>
</DOC>